Skip to main content

Teva Pharmaceutical Industries Ltd

corporate_fare Company Profile

Teva Pharmaceutical Industries Ltd

TEVA·NYSE·Life Sciences·CIK 0000818686

Teva is a biopharmaceutical company with a generics business, incorporated in Israel on February 13, 1944, succeeding a company established in 1901. The company operates worldwide, with headquarters in Israel and a significant presence in the United States, Europe, and other global markets. Teva's global network includes approximately 34,000 employees across 57 markets. Teva operates through three business segments: United States, Europe, and International Markets. Each segment manages the full product portfolio for its region, encompassing generics (including biosimilars and over-the-counter products) and innovative medicines. The United States Segment is a leading generic pharmaceutical company in the U.S., marketing over 350 generic prescription products in more than 1,100 dosage strengths, packaging sizes, and forms. These include oral solid dosage forms, injectable products, inhaled products, liquids, transdermal patches, ointments, and creams. Most U.S. generic sales are made to retail drug chains, mail order distributors, and wholesalers. Beyond these three segments, Teva's other activities primarily involve selling active pharmaceutical ingredients (API) to third parties, providing certain contract manufacturing services, and an out-licensing platform through its affiliate Medis, which offers a product portfolio to other pharmaceutical companies.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for TEVA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-11, rated 7/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for TEVA spans 8-K, FWP, 424B5, 10-Q.

Recent high-impact activity:

  • Teva Executes Underwriting Agreement for $4.9B Multi-Currency Senior Notes Offering
  • Teva Prices $3.2B Multi-Tranche Senior Notes Offering, Amends Redemption Plans
  • Teva Prices €1.5B Euro Senior Notes, Completing Multi-Tranche Refinancing
  • Teva Launches Multi-Tranche Senior Notes Offering to Refinance Debt
  • Teva Swings to Q2 Loss on $724M Emalex Charge; Terminates ADS Program

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$17.26B
Net Income
$1.41B
Diluted EPS
$1.21
Op. Cash Flow
$1.65B
Free Cash Flow
$1.15B
Gross Profit
$8.94B
Operating Income
$2.16B
Cash & Equivalents
$3.56B
Total Debt
$1.8B
Debt / Equity
0.23×
Net Margin
8.2%
Shares Outstanding
1.15B sh
Source: 10-K · filed 2026-02-03 · accession 0001193125-26-034532

Dilution Risk

Low risk

Filing-implied dilution signals for TEVA, detected from its recent SEC filings · based on capital-structure filings through 2026-09-11.

1 recent capital raise

Final Prospectus for $4.9B Notes Offering · Refinancing of Higher-Coupon Debt

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with T →
$37 -0.09% today
52-week range · as of 2026-09-11 $18.21 – $38.37
Market cap
$42.44B
Volume
2.9M (0.6× avg)
3-mo avg 5M
Live data · 2026-09-13 21:35 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TEVA - Latest Insights

TEVA
Sep 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $37.09
Real-time Price: $37.00 info
Change: -$0.090 (-0.24%) info
Market Cap: $42.444B info
TEVA
Sep 10, 2026, 6:04 AM EDT
Filing Type: FWP
Importance Score:
7
Price at Filing: $36.72
Real-time Price: $37.00 info
Change: +$0.280 (+0.76%) info
Market Cap: $42.444B info
TEVA
Sep 10, 2026, 6:01 AM EDT
Filing Type: FWP
Importance Score:
7
Price at Filing: $36.72
Real-time Price: $37.00 info
Change: +$0.280 (+0.76%) info
Market Cap: $42.444B info
TEVA
Sep 08, 2026, 6:54 AM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $36.16
Real-time Price: $37.00 info
Change: +$0.840 (+2%) info
Market Cap: $42.444B info
TEVA
Jul 29, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $34.73
Real-time Price: $37.00 info
Change: +$2.27 (+7%) info
Market Cap: $42.444B info
TEVA
Jul 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $32.45
Real-time Price: $37.00 info
Change: +$4.55 (+14%) info
Market Cap: $42.444B info
TEVA
Apr 29, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $35.54
Real-time Price: $37.00 info
Change: +$1.46 (+4%) info
Market Cap: $42.444B info
TEVA
Apr 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $33.39
Real-time Price: $37.00 info
Change: +$3.61 (+11%) info
Market Cap: $42.444B info
TEVA
Feb 03, 2026, 8:58 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $35.71
Real-time Price: $37.00 info
Change: +$1.29 (+4%) info
Market Cap: $42.444B info
TEVA
Jan 28, 2026, 7:20 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $32.14
Real-time Price: $37.00 info
Change: +$4.86 (+15%) info
Market Cap: $42.444B info
TEVA
Jan 12, 2026, 6:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.28
Real-time Price: $37.00 info
Change: +$2.72 (+8%) info
Market Cap: $42.444B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets